{
  "abstract": "Anti-GPIHBP1 syndrome is a rare, acquired cause of hypertriglyceridaemia, characterized by severe elevation of triglyceride that is refractory to standard lipid-lowering therapies. It is autoimmune in nature and demonstrates a significant response to immunosuppressive treatment. However, it has a chronic relapsing course and the role of maintenance immunosuppression in this syndrome remains unclear. We report a 46-year-old woman diagnosed with anti-GPIHBP1 syndrome following an initial presentation of acute pancreatitis. While her initial presentation and short-term induction response were previously reported, we would like to present her longitudinal follow-up, highlighting the long-term relapsing nature of the syndrome. She showed a good therapeutic response to intravenous rituximab infusions. Due to recurrent episodes of pancreatitis, maintenance immunosuppression with rituximab was commenced. Serial monitoring of CD19+ B-cell repopulation was used to guide the subsequent dosing timing as a hypothesis-generating strategy to aid in relapse prevention. During the latest follow-up, she remained in clinical and biochemical remission with proactive rituximab maintenance infusions. This single case observation suggests that patients with relapsing anti-GPIHBP1 syndrome might benefit from maintenance treatment with rituximab. Furthermore, regular monitoring of CD19+ B-cell repopulation may serve as a potential biomarker to guide retreatment, though it warrants further evaluation in more patients.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Case Report",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "Jun Min Em"
    },
    {
      "name": "Tharsini Sarvanandan"
    },
    {
      "name": "Jeyakantha Ratnasingam"
    },
    {
      "name": "Pavai Sthaneshwar"
    },
    {
      "name": "Masami Murakami"
    },
    {
      "name": "Soo Kun Lim"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fkzjqkhwgt2qc.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1972947",
  "fulltext_url": null,
  "id": "fkzjqkhwgt2qc",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1972947",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "feed-journal",
      "biology/immunology"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-02",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/fkzjqkhwgt2qc.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T12:20:45Z",
      "native_id": "10.3389/fimmu.2026.1972947",
      "source": "feed-frontiers",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1972947"
    },
    {
      "first_seen": "2026-11-02T12:23:23Z",
      "native_id": "10.3389/fimmu.2026.1972947",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1972947/full"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "feed-journal:biology/immunology",
      "subfield": "immunology"
    }
  ],
  "title": "Long-term management of relapsing anti-GPIHBP1 (Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1) associated hypertriglyceridaemia: a case report and literature review",
  "title_text": "Long-term management of relapsing anti-GPIHBP1 (Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1) associated hypertriglyceridaemia: a case report and literature review",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T00:25:32Z",
  "url": "https://research.draconitic.com/paper/fkzjqkhwgt2qc",
  "venue": "Frontiers in Immunology",
  "versions": []
}